GSK launches $50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies
8 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the launch of Action Potential Venture Capital (APVC) Limited...
List view / Grid view
News
Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival
7 August 2013 | By Novartis
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib...
FT Global Pharmaceutical and Biotechnology Conference
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer
6 August 2013 | By GlaxoSmithKline
“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline..."
Sanofi Pasteur initiates Phase III study of investigational Clostridium difficile vaccine
5 August 2013 | By Sanofi
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide...
Roche and the Medicines Patent Pool sign agreement to increase access to medicines to treat CMV infection in HIV-patients, a major cause of blindness
5 August 2013 | By Roche
The Medicines Patent Pool and Roche announce an agreement...
albiglutide US PDUFA date extended by three months
2 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide has been extended by three months...
Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints
1 August 2013 | By Boehringer Ingelheim
Data from the LUX-Lung clinical trial programme...
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]
1 August 2013 | By Novartis
Novartis announced that the US FDA approved Menveo®...
Sanofi appoints Carsten Hellmann and David Meeker to the Executive Committee
31 July 2013 | By Sanofi
Sanofi announced the appointment of two new members to the Executive Committee, effective September 1st, 2013...
AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease
31 July 2013 | By AstraZeneca
Collaboration to include US, China and selected other markets...
First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes
31 July 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the…
Tecan Cavro® components key to made-to-measure robotics
30 July 2013 | By kdm communications
LCTech GmbH has been using Tecan Cavro® components for many years...
New data for Abbott’s investigational High Sensitive Troponin test shows it may help doctors predict heart attack risk
30 July 2013 | By Abbott
Abbott announced promising results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay...
Lonza and BioWa sign license agreements with Pfizer, Inc.
BioWa, Inc. and Lonza today announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
